Jeffrey B Locke

6PUBLICATIONS
12CO-AUTHORS
Innate immunityMedical bacteriologyMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 18, 2025
Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice.

Simon Döhrmann, James Levin, Jason N Cole

|Sep 27, 2024
In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model.

Dávid Balázsi, Zoltán Tóth, Jeffrey B Locke

|Mar 25, 2024
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.

Jeffrey B Locke, Chris M Pillar, Mariana Castanheira

|Mar 07, 2023
Development and preliminary validation of a modified EUCAST yeast broth microdilution MIC method with Tween 20-supplemented medium for rezafungin.

Douglas E Zuill, Amanda L Almaguer, Joanna Donatelli

|Nov 04, 2022
Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin.

Maiken Cavling Arendrup, Sevtap Arikan-Akdagli, Mariana Castanheira

|Apr 24, 2018
Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.

Jeffrey B Locke, Amanda L Almaguer, Joanna L Donatelli

Pageof 1

Frequent Collaborators

2 joint publications

Maiken Cavling Arendrup

2 joint publications

Mariana Castanheira

1 joint publications

Sevtap Arikan-Akdagli

1 joint publications

Jesus Guinea